Most people who look for psilocybin treatment are not dealing with dependence. Federal research summaries say research to date suggests psilocybin use does not typically lead to addiction [1]. The fifth edition of the Diagnostic and Statistical Manual of Mental Disorders carries no substance use criteria specific to psilocybin, though it does include “other hallucinogen use disorder” [1].
What sends people to care is usually something else: a frightening experience that has not settled, a poisoning, or another substance underneath. This page covers those, how a level of care gets chosen, what therapy does here, and what it costs. Our page on magic mushroom abuse covers the substance itself.
If someone is having a seizure, is unresponsive or has trouble breathing, call 911. For a mental health crisis, call or text 988.
When Psilocybin Use Becomes Something Treatment Can Help With
Four situations, and the first two are physical rather than psychological.
Poisoning is one. Federal summaries note the risk of misidentifying mushrooms and taking a toxic one instead of one containing psilocybin [1]. They also report, citing the Centers for Disease Control and Prevention, that some commercial products such as candies marketed as containing psilocybin have been found to contain toxic chemicals and have caused severe illness [1]. Exposures reported to poison control centers have risen in recent years [1].
Acute effects needing care is another. Psilocybin typically raises blood pressure and heart rate, which may be dangerous for people with heart conditions [1]. Side effects such as agitation, confusion, vomiting or nausea may be severe and require medical attention [1].
The third is mental health, and it is the most common reason. Some people taking psilocybin experience extreme fear, anxiety, panic or paranoia while its effects last [1]. Federal summaries add a comparison worth knowing: the risk of problems such as psychosis or suicidality is low among people taking psilocybin in supervised clinical research, but poor mental health outcomes may be more likely with use outside clinical settings [1].
The fourth is everything else in the picture. Psilocybin is rarely the only substance involved, and often it is not the one causing the trouble.
Assessment: What a Clinician Looks For Before Recommending a Level of Care
The assessment sets the level of care. It is the appointment worth booking even when nothing else is decided.
For this substance, the questions run in a particular order. What was actually taken, including whether it was a mushroom, a product or something unidentified. Whether there were physical symptoms severe enough to need care. What the mental state has been like since, not just during. Whether fear, paranoia or perceptual changes have persisted. Whether there is a personal or family history of psychosis or bipolar disorder. And what else is being used.
Federal research guidance asks that a plan be tailored to the person, addressing their own drug use patterns alongside their drug-related medical, mental and social problems [2]. Here that usually means the plan is shaped by the mental health answer more than by the psilocybin answer.
Our rehab process page explains where the assessment sits, and our levels of care guide covers the options it weighs.
Does Psilocybin Need Medical Detox First?
No, not for psilocybin itself, and a program that tells you otherwise is selling something.
There is no recognized physical withdrawal syndrome for psilocybin, and federal summaries record that its use does not typically lead to addiction [1]. Withdrawal management is a level of care built for a different problem.
Detox enters the picture when something else does. Alcohol and benzodiazepines are the two whose withdrawal is a medical event rather than a discomfort, and where either is present the setting changes immediately. Federal guidance maps out those settings, from a physician’s office through freestanding programs and partial hospitalization to acute care inpatient units, aligned with the five adult detox levels used by the American Society of Addiction Medicine [3].
Even then, detox opens treatment rather than being it. Federal guidance states that detoxification is not substance abuse treatment and rehabilitation [4]. Federal research guidance adds that detox on its own generally leads back to drug use [2]. Our medical detox page covers the level of care, and our page on withdrawal symptoms compares drug classes.
An assessment, and care at every level, in Florida
Our campus at Umatilla, Florida, in Lake County northwest of Orlando, is The Recovery Village Umatilla. Medical detox, residential and inpatient care, inpatient rehab for mental health, a partial hospitalization program, outpatient care and aftercare planning all run from that one site. If you are not sure which of those applies, the assessment is the thing to ask for.
See treatment options in Florida
Verify your insurance
The Recovery Village Umatilla is part of our family of treatment centers. See the Recovery Village Umatilla campus.
Residential Treatment for Psilocybin Use, and Who It Suits
A residential bed is the right answer here only when something other than psilocybin makes it so.
That happens in three ways. A mental health crisis that needs daily psychiatric contact while it settles. A second substance whose withdrawal has to be managed. Or a living situation that cannot support any other plan.
Where none of those holds, being told that a bed is unnecessary is the useful answer, even though it is the one no marketing page gives. Our inpatient rehab page describes what living at a program involves, and our guide to how long rehab takes covers the arc.
PHP and IOP for Psilocybin Use
These are the levels that actually fit most of what arrives on this page.
A partial hospitalization program runs most of a clinical day, with the person sleeping elsewhere. An intensive outpatient program is lighter, typically a few hours several days a week, arranged around ordinary commitments.
Both suit this work because the work is psychological. Persistent fear, low mood, sleep disruption and the meaning someone has made of a difficult experience are all treatable in an outpatient frame. Where a psychiatrist is attached to the program, medication for those conditions can be reviewed weekly rather than monthly, which is usually the practical difference between the two levels.
Our outpatient rehab page sets out how those weeks are built.
Therapies With the Strongest Evidence for This Substance
With no medication for the use itself, therapy carries the plan.
Federal research guidance describes cognitive behavioral therapy as work that “seeks to help patients recognize, avoid, and cope with the situations in which they’re most likely to use drugs” [2]. It describes contingency management as positive reinforcement, such as rewards or privileges, for remaining drug free and for attending counseling [2]. It also notes that behavioral therapies help people stay in treatment longer [2].
Two questions are worth putting to any program on this subject. Does it treat anxiety and trauma-related conditions in-house, since those are frequently the actual target here. And is it comfortable working with someone whose difficult experience was a psychedelic one, which is a specific skill and not every clinician has it.
Our pages on substance abuse counseling techniques and on what CBT is describe those sessions.
Medication Options, Where They Exist
Nothing is approved to treat psilocybin use, and the more useful point is what medication is for here.
Federal research guidance sets out which drug classes have a medication behind them; this is not one of them, and where a class has none, treatment consists of behavioral therapies [2].
Meanwhile psilocybin is itself being studied as a possible clinical treatment for substance use disorders and other mental illnesses, with federal support [1]. That is not an answer to the question above, and the two get run together constantly. Research use happens under supervision inside a study.
What does get prescribed is what sits alongside: anxiety, low mood, sleep. Where another substance is in use, medication-assisted treatment may apply to that. No amounts or schedules appear on this page.
Co-occurring Mental Health Conditions and Why They Change the Plan
On this page this is not a footnote. It is the reason most people are reading.
Federal summaries note that psychosis and suicidality are uncommon among people taking psilocybin in supervised research, while poor mental health outcomes may be more likely with use outside clinical settings [1]. They also record the extreme fear, anxiety, panic and paranoia some people experience during use [1]. Where any of that has not resolved, it is a condition to treat rather than something to sit out.
Two practical points. Say plainly on the assessment call what has been happening in your head since, including anything that sounds strange to say out loud. And expect the recommendation to move toward daily clinical contact if the answer is significant.
Federal research guidance asks for a plan that addresses mental and social problems alongside drug use [2]. Our co-occurring conditions page explains how both are treated at once.
Paying for Psilocybin Treatment and Verifying Benefits
What your plan pays depends on the plan, and one phone call settles more than an afternoon of reading.
Parity rules are the backdrop. A plan that covers mental health and substance use benefits may not attach financial requirements or treatment limits to them that are tougher than the predominant ones it applies to substantially all medical and surgical benefits in the same classification [5]. Those rules reach non-federal governmental plans with more than 50 employees and private employer group plans with more than 50 employees, and individual-market coverage [5]. Small-employer group plans fall outside them, though non-grandfathered small-group and individual plans still have to include this care as an essential health benefit under the Affordable Care Act [5]. Marketplace plans carry no yearly or lifetime dollar limit on it [6].
For a rough sense of scale, our own what rehab costs page publishes $350 to $450 a day for partial hospitalization and $3,000 to $10,000 for a 30-day intensive outpatient program. Those are our ranges, not federal figures. Our insurance coverage guide covers the verification call, how to get into rehab covers admissions, and our nationwide directory of rehab facilities lists our campuses.
Frequently Asked Questions
Do I need inpatient treatment for psilocybin use? Rarely for psilocybin by itself. Federal summaries say research to date suggests its use does not typically lead to addiction. A bed makes sense when a mental health crisis needs daily psychiatric contact, when another substance has to be withdrawn from safely, or when home cannot support any other plan. The assessment settles it.
Is there a medication for psilocybin addiction? No. Federal research guidance sets out which drug classes have medications behind them, and this is not one; where a class has none, treatment consists of behavioral therapies. Do not confuse that with psilocybin being studied as a possible treatment for other conditions, which is a separate question answered inside research settings.
How long does psilocybin treatment take? It depends on what is being treated. Where a mental health condition is the target, the timeline belongs to that condition. Where substance use is, federal research guidance holds that most people need at least three months in treatment to significantly reduce or stop drug use, with better outcomes at longer durations. That counts time across every level of care.
Will insurance cover it? Commonly, at least in part, and the policy decides the rest. Parity rules prevent a plan that covers this care from applying limits tougher than the predominant ones on substantially all its medical and surgical benefits. A Marketplace plan carries no yearly or lifetime dollar limit on it. Ask admissions to run the verification and put the answer in writing.
What happens on the first call? It is a screening, held in confidence, and nothing is committed to. Expect questions about what was taken and how often, anything else in use, previous treatment, current prescriptions, other diagnoses, and what home looks like. Coverage is usually checked in the same call. The clinical assessment comes next and decides the level of care.
Sources
- National Institute on Drug Abuse. Psilocybin (Magic Mushrooms). National Institutes of Health. https://nida.nih.gov/research-topics/psilocybin-magic-mushrooms
- National Institute on Drug Abuse. Drugs, Brains, and Behavior: The Science of Addiction — Treatment and Recovery. National Institutes of Health. https://nida.nih.gov/publications/drugs-brains-behavior-science-addiction/treatment-recovery
- Center for Substance Abuse Treatment. (2006). Detoxification and Substance Abuse Treatment, Chapter 2: Settings, Levels of Care, and Patient Placement. Treatment Improvement Protocol (TIP) Series No. 45, SAMHSA, via NCBI Bookshelf. https://www.ncbi.nlm.nih.gov/books/NBK64109/
- Center for Substance Abuse Treatment. (2006). Detoxification and Substance Abuse Treatment, Chapter 1: Overview, Essential Concepts, and Definitions in Detoxification. Treatment Improvement Protocol (TIP) Series No. 45, SAMHSA, via NCBI Bookshelf. https://www.ncbi.nlm.nih.gov/books/NBK64119/
- Centers for Medicare and Medicaid Services. The Mental Health Parity and Addiction Equity Act (MHPAEA). https://www.cms.gov/marketplace/private-health-insurance/mental-health-parity-addiction-equity
- HealthCare.gov. Mental Health and Substance Abuse Health Coverage Options. Centers for Medicare and Medicaid Services. https://www.healthcare.gov/coverage/mental-health-substance-abuse-coverage/
- National Institute on Drug Abuse. (2012). Principles of Drug Addiction Treatment: A Research-Based Guide, 3rd edition. National Institutes of Health. https://nida.nih.gov/sites/default/files/podat-3rdEd-508.pdf
This page is for general information and is not medical advice. Only a licensed clinician who knows your history can tell you what is right for you. If you or someone you know is in immediate danger, call 911. For free, confidential support 24/7, call or text 988.
Author
Chief Medical Officer,
The Recovery Village
